Oligomerix Relocates Headquarters to Accommodate Growth

Oligomerix Awarded a $3.19 Million Grant from NIA BioWorld

Oligomerix Receives $3.19 Million NIH Commercialization Readiness Pilot Grant for Alzheimer’s Disease Therapy

Oligomerix to Present at AAIC 2020 Conference on Small Molecule Inhibitor of Tau Self-Association

Oligomerix Appoints William Erhardt, M.D., as Chief Medical Officer

Oligomerix Announces Appointment of Robert Foerster, Former Pfizer Executive, as Chief Financial Officer

Oligomerix Presents Preclinical Data at TAU2020 Global Conference for Small Molecule Inhibitor of Tau Self-Association

Oligomerix to Present at BIO CEO & Investor Conference, Tau2020 Global Conference

Study Might Point Alzheimer’s Research in Whole New Direction U.S. News

Newly Discovered Drug Is Able To Inhibit Neurotoxic Tau Oligomers In Brains, Paving The Way For A Potential Cure for Alzheimer